Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046271 | 0.86 | KEAP1 (0.53) | PIM1EPHX2KDM4EKMT2AIGF2BP2 | |
| SCHEMBL2314619 | 0.86 | CHEK1 (0.47) | CHEK1PIM1MAPK8JAK2EPHX2 | |
| SCHEMBL30236136 | 0.86 | CHEK1 (0.47) | CHEK1PIM1MAPK8JAK2EPHX2 | |
| SCHEMBL6518415 | 0.86 | CHEK1 (0.49) | CHEK1PIM1MAPK8JAK2EPHX2 | |
| SCHEMBL13043978 | 0.85 | PIM1 (0.43) | PIM1EPHX2GAAKDM4EKMT2A | |
| SCHEMBL30951611 | 0.85 | PIM1 (0.43) | PIM1EPHX2GAAKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL27647270 | 0.85 | KMT2A (0.53) | PIM1EPHX2KDM4EKMT2AIGF2BP2 | |
| SCHEMBL1438883 | 0.83 | KDM4E (0.55) | PIM1EPHX2GAAKDM4EKMT2A | |
| SCHEMBL9372777 | 0.83 | P2RX1 (0.47) | CHEK1PIM1MAPK8JAK2EPHX2 | |
| SCHEMBL13407882 | 0.83 | CHEK1 (0.47) | CHEK1BRAFPIM1MAPK8JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262784-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-08-20 | — | — | US | disclosed |
| US-10676424-B2 | Trifluoromethoylation of arenes via intramolecular trifluoromethoxy group migration | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190016670-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170298008-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-10-19 | — | — | US | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| CN-101155802-A | Crystal of aminopyrrolidine derivative and prodcution method thereof | TEIJIN PHARMA LTD (JP) | 2008-04-02 | — | — | CN | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| CN-1976907-A | Heterocyclic amide compound and use thereof as an MMP-13 inhibitor | TAKEDA PHARMACEUTICAL (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1740551-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016670-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | AHR, ARSA, ALK | CHEK1 3740/4885IKBKB 2685/4885HDAC3 388/4885 |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | CHEK1 721/4885IKBKB 2577/4885HDAC3 3168/4885 |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | CHEK1 4702/4885IKBKB 490/4885HDAC3 16/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | CHEK1 4776/4885IKBKB 750/4885HDAC3 8/4885 |
| US-20170298008-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | AHR, ARSA, ALK | CHEK1 3705/4885IKBKB 2855/4885HDAC3 428/4885 |
| US-20200262784-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | AHR, AFF2, AFF4 | CHEK1 3937/4885IKBKB 3027/4885HDAC3 409/4885 |
| US-10676424-B2 | Trifluoromethoylation of arenes via intramolecular trifluoromethoxy group migration | AHR, AFF2, AFF4 | CHEK1 3708/4885IKBKB 2680/4885HDAC3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.